Doctors urge GLP-1 users not to stop treatment over the new vision-loss warning
_Image credit: Business Standard_
After the FDA's 9 November order to add a NAION warning to all GLP-1 labels, specialists told Business Standard that the absolute risk is very low and should be weighed against the metabolic and heart benefits. They advise patients to get any sudden vision change checked rather than stopping medicine on their own. The EMA already lists NAION as a very rare side effect of semaglutide.
Source: Business Standard (12 Nov 2026). Image: Business Standard.